Merdury Biopharmaceutical Corporation (TPEX:6932)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
8.89
+0.12 (1.37%)
At close: Feb 26, 2026
-45.46%
Market Cap 3.72B
Revenue (ttm) 246.00K
Net Income (ttm) -70.59M
Shares Out 418.44M
EPS (ttm) -0.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 465,901
Average Volume 914,370
Open 8.77
Previous Close 8.77
Day's Range 8.75 - 9.00
52-Week Range 4.95 - 17.45
Beta -2.63
RSI 50.21
Earnings Date Apr 2, 2026

About Merdury Biopharmaceutical

Merdury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan. The company develops StackDose platform, a drug development technology platform that integrates drug formulation, 3D powder printing, and hardware and software technologies to create drug-specific 3D printing production equipment, which can be used as a foundation for pharmaceutical companies to provide hosted services and in-house product development. Merdury Biopharmaceutical Corporation was founded in 2019 and is headquartered in New Taipei C... [Read more]

Sector Healthcare
Founded 2019
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6932
Full Company Profile

Financial Performance

In 2024, Merdury Biopharmaceutical's revenue was 4.96 million, an increase of 380.45% compared to the previous year's 1.03 million. Losses were -50.57 million, 15.4% more than in 2023.

Financial Statements

News

There is no news available yet.